Arthritis Research & Therapy

Table 2 Studies of flow-mediated dilatation in systemic sclerosis

From: Cardiovascular disease in systemic sclerosis - an emerging association?

Reference	Total SSc number	lSSc number	dSSc number	Controls number	Outcome^a	Other findings
Lekakis et al. [40], 1998	12	0	12	12	↓	NMD ↓. Improvement was found in FMD after estrogen administration.
Andersen et al. [44], 2002	24	20	4	24	↔	NMD ↔
D'Andrea et al. [42], 2007	33	18	15	33	↓	NMD ↔. FMD was a predictor of middle LV strain on TTE.
Szucs et al. [28], 2007	29	19	10	29	↓	NMD ↔
Sfikakis et al. [39], 2007	24	6	18	52	↓	NMD ↔. Four weeks of bosentan led to improvement in FMD.
Bartoli et al. [38], 2007	35	24	11	20	↓	No correlation between FMD and cardiovascular risk factors was found.
Roustit et al. [27], 2008	42	33	9	33	↔	NMD ↔
Cypiene et al. [37], 2008	17	0	17	34	↓	NMD ↔
Rollando et al. [43], 2010	43	30	13	27	↓	FMD was inversely correlated with microvascular damage on nailfold videocapillaroscopy.
Rossi et al. [45], 2010	14	10	4	14	↓	NMD ↓

^aFlow-mediated dilatation (FMD) in patients with systemic sclerosis (SSc) relative to controls: ↓, lower in patients with SSc than controls; ↔, no difference between patients with SSc and controls. dSSc, diffuse systemic sclerosis; lSSc, limited systemic sclerosis; LV, left ventricle; NMD, nitroglycerin-mediated dilatation; TTE, trans-thoracic echocardiography.

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com